These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11679916)

  • 1. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users.
    Barber Y; Rubio C; Fernández E; Rubio M; Fibla J
    J Infect Dis; 2001 Nov; 184(10):1279-88. PubMed ID: 11679916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients.
    Nieto G; Barber Y; Rubio MC; Rubio M; Fibla J
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):199-207. PubMed ID: 15225772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine receptor polymorphisms and human immunodeficiency virus disease progression.
    Easterbrook PJ; Rostron T; Ives N; Troop M; Gazzard BG; Rowland-Jones SL
    J Infect Dis; 1999 Oct; 180(4):1096-105. PubMed ID: 10479136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
    Wasik TJ; Smoleń J; Kruszyński P; Bratosiewicz-Wasik J; Beniowski M
    Wiad Lek; 2005; 58(9-10):500-7. PubMed ID: 16529059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.
    Morawetz RA; Rizzardi GP; Glauser D; Rutschmann O; Hirschel B; Perrin L; Opravil M; Flepp M; von Overbeck J; Glauser MP; Ghezzi S; Vicenzi E; Poli G; Lazzarin A; Pantaleo G
    Eur J Immunol; 1997 Dec; 27(12):3223-7. PubMed ID: 9464809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users.
    Schinkel J; Langendam MW; Coutinho RA; Krol A; Brouwer M; Schuitemaker H
    J Infect Dis; 1999 Apr; 179(4):825-31. PubMed ID: 10068577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
    Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
    Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection.
    Singh KK; Barroga CF; Hughes MD; Chen J; Raskino C; McKinney RE; Spector SA
    J Infect Dis; 2003 Nov; 188(10):1461-72. PubMed ID: 14624371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
    Mulherin SA; O'Brien TR; Ioannidis JP; Goedert JJ; Buchbinder SP; Coutinho RA; Jamieson BD; Meyer L; Michael NL; Pantaleo G; Rizzardi GP; Schuitemaker H; Sheppard HW; Theodorou ID; Vlahov D; Rosenberg PS;
    AIDS; 2003 Feb; 17(3):377-87. PubMed ID: 12556692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS.
    Gabutero E; Moore C; Mallal S; Stewart G; Williamson P
    AIDS; 2007 Jan; 21(1):65-9. PubMed ID: 17148969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
    Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
    J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users.
    de la Torre MS; Torres C; Nieto G; Vergara S; Carrero AJ; Macías J; Pineda JA; Caruz A; Fibla J
    J Infect Dis; 2008 Feb; 197(3):405-10. PubMed ID: 18205531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians.
    Kaur G; Singh P; Rapthap CC; Kumar N; Vajpayee M; Sharma SK; Wanchu A; Mehra NK
    Hum Immunol; 2007 May; 68(5):454-61. PubMed ID: 17462514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children.
    Ometto L; Bertorelle R; Mainardi M; Zanchetta M; Tognazzo S; Rampon O; Ruga E; Chieco-Bianchi L; De Rossi A
    J Infect Dis; 2001 Mar; 183(5):814-8. PubMed ID: 11181160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 chemokine receptor genotype frequencies among Puerto Rican HIV-1-seropositive individuals.
    Gonzalez S; Tirado G; Revuelta G; Yamamura Y; Lu Y; Nerurkar VR; Yanagihara R
    Bol Asoc Med P R; 1998; 90(1-3):12-5. PubMed ID: 9734151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population.
    Apostolakis S; Baritaki S; Krambovitis E; Spandidos DA
    J Clin Virol; 2005 Dec; 34(4):310-4. PubMed ID: 16286055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations in CC chemokine receptors and hypertension.
    Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
    Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.